Integrating antibodies against EpCAM, HER2, and EGFR in CTC isolation platforms improved capture rates and provided a more comprehensive profile of CTC populations in breast and non-small cell lung cancer patients [28,95,96]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.